Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Shareholder vote
confidence 95%
filed 2026-05-21
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on May 21, 2026, where shareholders voted on the approval of a merger agreement with AC Residential Acquisition LP and related transactions. The Merger Proposal received overwhelming approval (76,820,975 FOR votes vs. 18,230 AGAINST), representing a material change of control event. The filing explicitly presents voting results for multiple proposals, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on May 20, 2026. The filing reports voting outcomes on four proposals: election of seven directors, ratification of the independent auditor (EisnerAmper LLP), advisory vote on named executive officer compensation, and approval of a stock option exchange program. The detailed vote tallies for each proposal and nominee are the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
VIAVI Solutions conducted a public offering of 11,111,111 shares of common stock at $45.00 per share, with underwriters exercising an additional 1,666,666 shares under the greenshoe option, generating approximately $557.2 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and cash position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 3.03
CarParts.com implemented a 1-for-10 reverse stock split, effective May 25, 2026, following stockholder approval on May 11, 2026. The reverse split modifies the company's capital structure, affects share count and trading mechanics, and results in a new CUSIP number.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-21
Item 1.01
The filing discloses entry into material definitive agreements in connection with the issuance of Asset Backed Notes by Mercedes-Benz Auto Receivables Trust 2026-1 on May 20, 2026. This represents a material securitization transaction involving the creation and issuance of structured debt securities backed by auto receivables, which constitutes a material financing activity requiring Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
CareTrust REIT completed a public offering of 12.5 million firm shares plus 1.875 million optional shares of common stock at $40.225 per share, totaling approximately 14.375 million shares. The filing discloses the underwriting agreement, exercise of the option, and forward sale agreements executed on May 20-21, 2026. This is a material dilutive equity issuance that would significantly affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 filing discloses the results of three shareholder votes at Bank7 Corp.'s annual meeting held May 20, 2026: election of seven directors, ratification of RSM US LLP as independent auditor for 2026, and advisory approval of 2025 named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The Board approved a new Change in Control Employment Agreement with Vincent P. Berger II, Executive Vice President and Chief Financial Officer, effective June 1, 2026, detailing severance benefits, eligibility triggers, and compensation arrangements in the event of a change in control and termination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
HNI Corporation's annual meeting of shareholders held on May 20, 2026 resulted in the election of three directors (Hartnett, Porcellato, and Sivajee), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a classic Item 5.07 disclosure of shareholder meeting results held on May 20, 2026. The filing presents voting tallies for three proposals: election of 12 directors (with individual vote counts for each nominee), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. All three proposals passed with substantial majorities, making this a routine but material governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Insulet Corp held its 2026 Annual Meeting of Stockholders on May 20, 2026, with voting results disclosed for three proposals: election of three Class I directors (Luciana Borio, Michael R. Minogue, Timothy C. Stonesifer), advisory approval of executive compensation (Say-on-Pay), and ratification of PricewaterhouseCoopers LLP as independent auditor.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 5.03
Insulet Corp amended and restated its Bylaws to establish exclusive forum selection provisions for derivative actions, fiduciary duty claims, and Securities Act claims, affecting shareholders' litigation rights and corporate governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a standard Item 5.07 disclosure of shareholder voting results from the 2026 Annual Meeting held on May 19, 2026. The filing reports results for five proposals: election of seven directors, approval of an amendment to the 2024 Omnibus Equity Incentive Plan, advisory approval of executive compensation, advisory approval of compensation vote frequency, and ratification of Cherry Bekaert LLP as independent auditors. All proposals passed with substantial majorities, making this a routine but material shareholder governance disclosure.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Aebi Schmidt held its Annual Meeting on May 21, 2026, with shareholders voting on 11 proposals including election of directors, approval of audited financial statements, dividend distribution, and executive compensation matters. All proposals were approved by shareholders with strong majorities.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 95%
filed 2026-05-21
Item 5.02
Shareholders approved the Aebi Schmidt Equity Incentive Plan, which authorizes the Board to grant restricted share units, performance share units, and restricted shares to executives, employees, and non-executive Board members, with 3.5 million shares authorized and performance-based incentive provisions.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Beta Bionics announced an updated commercialization timeline for its lead product candidate, Mint ACE insulin pump, expecting full commercialization by end of Q2 2027 subject to FDA clearance. This material product development milestone affects investor assessment of the company's near-term revenue prospects and regulatory progress.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 2.01
RTB Digital completed a merger transaction, resulting in a change of control of the registrant. The merger involved the reconstitution of the Board with multiple director resignations and appointments, and the Board was resized to seven members.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-21
Item 5.02
Following the merger closing on May 21, 2026, RTB Digital appointed four new executive officers: James Heckman as CEO, Aly Madhavji as CFO, George Oliva as Chief Accounting Officer, and William Sornsin as COO.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 3.02
RTB Digital issued approximately 13.1 million unregistered shares pursuant to Section 4 exemptions, comprising 7.7 million shares from convertible debt conversion, 2.1 million shares from warrant exercise, and 3.4 million shares from option exercise, materially diluting existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
This Item 7.01 disclosure presents BREIT's Q1 2026 quarterly update, including performance metrics (+2.0% net return), portfolio composition, and strategic positioning. While it contains performance data and forward-looking commentary on real estate markets and BREIT's investment strategy, it does not constitute a formal earnings release (no complete financial statements or standardized earnings metrics), nor does it fit cleanly into other specific event categories. The disclosure is material to investors as it provides substantive updates on fund performance, portfolio allocation, and capital deployment, but the format and content are more consistent with a general investor update than a traditional earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing "operating and financial results for its first quarter ended May 2, 2026," which is a standard quarterly earnings release. The press release is attached as Exhibit 99.1 and incorporated by reference, consistent with Item 2.02 earnings disclosures. This is material to investors assessing the company's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses financial results for the first quarter ended April 25, 2026 via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which is material to investors as it provides quarterly financial performance information essential to assessing the registrant's operating results and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
The filing discloses a press release announcing financial results for the quarter ended March 31, 2026, filed under Item 2.02 (Results of Operations and Financial Condition). This is a standard earnings release disclosure with the press release furnished as Exhibit 99.1, which is material to investors assessing the company's operational and financial performance.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-05-21
Item 1.01
Equity Residential entered into an Agreement and Plan of Merger with AvalonBay Communities, Inc., structured as an all-stock merger-of-equals transaction with an exchange ratio of 2.793 Equity Residential Common Shares per AvalonBay share. Both boards unanimously approved the transaction, which constitutes a material acquisition and change of control requiring shareholder approval, supported by a $2 billion bridge financing commitment.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 75%
filed 2026-05-21
Item 5.02
Equity Residential amended and restated the Change in Control Agreement with Mark J. Parrell, modifying his severance formula to 2.25x base salary plus target bonus and equity grant, plus 27 months of benefits continuation in connection with the merger transaction.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-05-21
Item 5.02
Matthew J. Peterson, Executive Vice President and President of Behavioral Health, resigned effective June 19, 2026, after seven years with the company. While the filing also addresses compensatory arrangements (forfeiture of unvested equity and termination of benefits), the principal disclosed action is Peterson's departure from a senior executive role overseeing a major division. The CEO will assume interim responsibilities while a permanent replacement is sought, indicating material operational impact.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 7.01
The FDA reclassified non-invasive bone growth stimulators from Class III to Class II, triggering CMS reimbursement changes that reduce Medicare reimbursement by approximately 10% for HCPCS codes E0747, E0748, and E0760. This regulatory action materially impacts Orthofix's financial outlook, forcing the company to lower full-year 2026 net sales guidance to $838–$848 million and adjusted EBITDA to $90–$93 million, and to withdraw its three-year financial targets. While this is a material event affecting investor assessment, it does not fit neatly into the more specific categories (it is neither a restatement, impairment, covenant breach, nor litigation), making "other_material" the most appropriate classification.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-05-21
Item 1.01
Corbus Pharmaceuticals appointed Nishant Saxena as Chief Business Officer effective May 21, 2026, under a two-year employment agreement with base salary of $470,000 and equity grants of 192,300 stock options and 58,300 RSUs.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
Brent Pfeiffenberger received equity compensation awards in connection with his Board appointment: a nonqualified stock option for 24,700 shares and a restricted stock unit award for 7,500 shares, both vesting over three years.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Devon Energy completed the acquisition of 16,300 net undeveloped acres in the Delaware Basin for approximately $2.6 billion, a material transaction representing significant expansion of the company's oil and gas asset base.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-05-21
Item 5.02
Michael A. Shriner's separation from his positions as President and Chief Executive Officer of BCB Bancorp and its subsidiary, along with his departure from both boards, is the principal disclosed action. While the filing also mentions Ryan Blake's appointment as Interim President and CEO, the prose centers on Shriner's departure as the triggering event. The departure of a CEO is material to investors assessing the registrant's leadership and governance.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 88%
filed 2026-05-21
Item 3.02
Seagate entered into exchange agreements to convert $185.908 million principal amount of exchangeable notes into cash and ordinary shares issued pursuant to Section 4(a)(2) exemption from registration. The transaction materially affects the company's capital structure and results in dilution to existing shareholders through the issuance of unregistered equity securities.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from River Financial Corp's 2026 Annual Meeting of Stockholders held on May 19, 2026. The filing presents the election of nine director nominees with detailed vote tallies (Votes For, Against, Abstain, and Broker non-votes) for each candidate, which is the quintessential content of Item 5.07 shareholder vote results disclosures. Director elections are material governance events affecting investor assessment of board composition and control.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-21
Item 8.01
The filing explicitly states that Urban Outfitters issued an earnings release on May 20, 2026, disclosing "material non-public information regarding the Company's earnings for the three months ended April 30, 2026." This is a direct disclosure of quarterly financial results, which is the core definition of an earnings_release event. The characterization as "material non-public information" and the attachment of the earnings release as Exhibit 99.1 confirm this classification.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from Phathom Pharmaceuticals' 2026 Annual Meeting held on May 19, 2026. The filing presents final voting tallies for three proposals: election of Class I directors (Steven Basta, Theodore R. Schroeder, Mark Stenhouse), ratification of Ernst & Young LLP as independent auditor, and advisory approval of named executive officer compensation. This is a routine but material Item 5.07 disclosure required by SEC rules.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Chart Industries disclosed a material acquisition by Baker Hughes under Item 8.01 (Other Events). The filing reports that on July 28, 2025, Chart entered into an Agreement and Plan of Merger with Baker Hughes, whereby Chart will be acquired and survive as an indirect wholly owned subsidiary of Baker Hughes. The disclosure further notes that Baker Hughes filed a Form CO with the European Commission on May 21, 2026, initiating Phase I regulatory review, with expected closing in July 2026. This constitutes a material M&A transaction requiring disclosure under Item 1.01 or analogous provisions, though reported here under Item 8.01 as a regulatory milestone update.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-21
Item 1.01
Research Alliance Corp III consummated its IPO on May 21, 2026, entering into material definitive agreements including an Underwriting Agreement, Investment Management Trust Agreement, and Private Placement Shares Purchase Agreement, raising $75 million in gross IPO proceeds and establishing the company's framework for future business combinations.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
The Sponsor purchased 275,000 Class A ordinary shares at $10.00 per share for $2.75 million in proceeds pursuant to Section 4(a)(2) of the Securities Act, representing an unregistered private placement concurrent with the IPO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-21
Item 5.02
Michael F. MacLean and Timothy J. Miller were appointed to the Board of Directors effective May 19, 2026, in connection with the Company's IPO, with concurrent appointments to the Audit, Nominating, and Compensation committees.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 5.03
The company adopted an Amended and Restated Memorandum and Articles of Association in connection with its IPO on May 19, 2026, establishing the company's post-IPO governance structure and shareholder rights.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-05-21
Item 8.01
Baker Hughes discloses a material acquisition of Chart Industries pursuant to a Merger Agreement dated July 28, 2025. The filing reports progress toward closing: completion of pre-notification with the European Commission and filing of a Form CO on May 21, 2026, initiating Phase I regulatory review. The company expects the merger to close in July 2026, subject to regulatory approvals and customary closing conditions. This is a significant M&A transaction requiring SEC disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-21
Item 5.02
Lukas Biewald was appointed to the Board of Directors effective May 20, 2026, and concurrently appointed to the Nominating and Corporate Governance Committee. The appointment includes compensatory arrangements consisting of RSU awards and cash retainers.
View raw filing on EDGAR →
8-K
M&A activity
confidence 75%
filed 2026-05-21
Item 1.01
Lumen Technologies' subsidiary Level 3 Financing completed a $1.0 billion offering of senior notes and entered into an indenture on May 21, 2026. The transaction includes change-of-control provisions, restrictive covenants, and guarantees from the parent and material subsidiaries, with proceeds used to fund concurrent tender offers.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-05-21
Item 2.02
Flowers Foods disclosed financial results for the 16-week period ended April 25, 2026, via press release filed under Item 2.02.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The company reset its dividend policy, reducing the annual dividend rate to $0.50 per share and declaring a quarterly dividend of $0.1250 per share, representing a significant change to shareholder return policy.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This 8-K Item 5.07 discloses the results of Hyperfine's 2026 annual meeting of stockholders held on May 21, 2026, including the reelection of five board directors (Daniel J. Wolterman, Maria Sainz, John Dahldorf, Ruth Fattori, and Jonathan M. Rothberg, Ph.D.) and the ratification of Grant Thornton LLP as independent auditor, with detailed vote tallies for each proposal. The disclosure of shareholder meeting results is a material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder voting results from BrightSpring's 2026 Annual Meeting of Stockholders held on May 21, 2026. The filing reports the outcomes of three proposals: election of three Class II directors (Olivia Kirtley, Max Lin, and Steve Miller), ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. All three items were approved. This is a material event as it reflects shareholder approval of board composition and auditor selection, which are fundamental governance matters affecting investor confidence.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 disclosure reports the results of TransMedics' 2026 Annual Meeting of Shareholders held on May 20, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, amendment to the 2019 Stock Incentive Plan, and ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed vote tallies for each proposal are material to shareholders' understanding of governance and corporate direction.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Shareholders voted at the Annual Meeting held on May 20, 2026, approving the election of eleven directors, an advisory vote on named executive officer compensation, an amendment and restatement of the Employee Stock Purchase Plan increasing authorized shares from 100,000 to 400,000, and the ratification of Deloitte & Touche LLP as independent auditor.
View raw filing on EDGAR →